Poco announced that it has entered into a definitive agreement to acquire Silk Road Medical for $27.50 per share, for a total consideration of approximately $1.16 billion. This is the second-largest acquisition in the cardiovascular space this year, and the second-largest acquisition of the year by Poco (after the acquisition of A xonics at the beginning of the year, although there is a lot of litigation between Axonics and Medtronic, and it is doubtful that the acquisition will be completed this year). The acquisition is expected to close in the second half of this year, and once completed, it is expected to bring Poco $194 million to $198 million in net income this year, an increase of 1 0-12% over the previous fiscal year.
Executive Testimonials "The TCAR platform developed by Silk Road Medical is a significant advancement in vascular medicine that has revolutionized stroke prevention and the treatment of carotid artery disease. We believe that the addition of this clinically differentiated technology to our vascular portfolio demonstrates our continued commitment to providing meaningful innovation to physicians caring for patients with peripheral vascular disease." --- Cat Jennings President of Vascular, Peripheral Interventions, Boston Scientific Silk Road Medica l is the pioneer of transcarotid revascularization (TCAR). Previously, for patients with moderate to severe carotid artery disease, only two surgical methods were used: carotid endarterectomy (CEA) and transfemoral carotid artery stenting (TFCAS, stenting), but these two treatments often bring many complications (such as cerebral infarction). However, T CAR surgery circumvents the shortcomings of endometrial decortication and stent implantation, and can "reverse" the blood flow during surgery, which not only prevents the detached plaque fragments from flowing to the brain, but also filters out plaque fragments outside the body, greatly reducing the risk of cerebral infarction.
Silk Road Medica l published a study of nearly 400,000 patients with carotid artery revascularization in the United States, showing that the incidence of cerebral infarction and myocardial infarction after TCAR was lower compared with endarterectomy; Compared with stenting, cerebral infarction and mortality were lower after TCAR. More than 80,000 TCAR surgeries have been performed in the United States, and TCARs are rapidly replacing the other two traditional procedures in the United States.
The TCAR surgery and related products developed by Silk Road Medica l are revolutionary, and once acquired, the acquisition of Boco will enrich Boco's peripheral product line, giving Boco a greater voice in the field of peripheral carotid arteries.
However, for an ambitious company like Poco, the acquisition of Silk Road Medica l is a small addition to the peripheral sector. Missing out on Shockwave is an eternal pain in Poco's heart. Compared with IVL, the market capacity of TCAR is too small, so it has only completed nearly 90,000 surgeries in the past 15 years. The IVL market capacity far exceeds that of TC AR, which is an order of magnitude difference. Poco can only sigh that Qian Duo (Johnson & Johnson) is really good. ENROUTE
The Transcarotid Vascular Reconstruction (TCAR) procedure pioneered by Silk Road Medical consists of two core products:
- ENROUTE Transcarotid Neuroprotection System(ENROUTE经颈动脉逆流血栓保护装置）
The "ENROUTE Thromboprotective Device" reverses blood flow to the brain before passing through the lesion, providing embolic protection during angioplasty and stenting. It provides embolic protection throughout the procedure through a reflux method of blood, rather than the traditional reliance on distally placed filters to capture blood clots. Small and large debris are collected through a filter in the flow controller, and the filtered blood is returned through a sheath in the femoral vein, resulting in CEA-like neuroprotection. The "ENROUTE thromboprotective device" is the core technology of the entire TCAR surgery, and it is also the key to distinguish TFCAS surgery.
- ENROUTE Transcarotid Stent System(ENROUTE®经颈动脉支架系统)
Designed specifically for TCAR surgery, the "ENROUTE stent" automatically conforms to the anatomy and provides long-term plaque stability to prevent future strokes.
Features include: Specific conveyor lengths: 57mm conveyor system for ergonomic and precise stent transport Optimized unit design: Provides maximum coverage of all open cell stent designs and is able to automatically adapt to even the most difficult anatomical structures
ENROUTE DEMO
Silk Road Medical
Silk Road Medical is an innovative medical device company based in California focused on reducing the risk of stroke and its devastating effects. Silk Road Medical has pioneered a new treatment for carotid artery disease called transcarotid revascularization (TCAR). TCAR is a clinically proven procedure that combines the surgical principles of neuroprotection with minimally invasive endovascular techniques for the treatment of carotid artery blockages at risk of stroke.